BofA Lowers Somnigroup Price Target to $96
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
BofA lowered the firm's price target on Somnigroup (SGI) to $96 from $106 and keeps a Buy rating on the shares after the company announced an agreement to acquire Leggett & Platt (LEG) in an all-stock merger for $2.5B. The firm, which thinks Leggett would be a good strategic fit and Somnigroup paid an attractive price, estimates 12% EPS accretion in 2027 pre-synergies. However, the firm lowers its 2026 EPS by 4%, in-line with the mid-point of Somnigroup's guidance, to reflect input inflation and a tougher macro environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGI
Wall Street analysts forecast SGI stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 79.200
Low
86.00
Averages
98.60
High
110.00
Current: 79.200
Low
86.00
Averages
98.60
High
110.00
About SGI
Somnigroup International Inc. is a bedding company. The Company is engaged in the business of designing, manufacturing, distributing and retailing. Its portfolio of product brands includes various brands, including Tempur-Pedic, Sealy and Stearns & Foster. Its portfolio of retail brands includes Mattress Firm, Dreams, Tempur-Pedic retail stores, SOVA and a variety of other retail brands internationally, which operate in various countries. The Company operates in three segments: Tempur Sealy North America, Tempur Sealy International and Mattress Firm. It sells products through two channels in each operating business segment: Wholesale and Direct. Its Wholesale channel consists of third-party retailers, including third-party distribution, hospitality and healthcare. Its Direct channel includes Company-owned stores, e-commerce and call centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Stock Price Movements of Various Companies
- Oracle AI Capabilities Boost: At the Customer Edge Summit, Oracle announced that its AI platform helped residential utility customers save $369 million in 2025, leading to a more than 9% increase in shares, indicating enhanced competitiveness in the cloud computing sector.
- Conagra CEO Transition: Conagra announced that John Brase will take over as CEO on June 1, resulting in a more than 5% drop in shares, reflecting market unease over leadership changes, with shares down over 17% in 2026.
- Allogene Therapeutics Clinical Success: The biotech company saw its shares soar nearly 30% after positive phase 2 data showed its CAR T treatment significantly improved cancer cell eradication in lymphoma patients, laying a strong foundation for future product line expansion.
- Goldman Sachs Earnings Beat: Despite its fixed income trading falling short of expectations, Goldman Sachs posted an earnings and revenue beat in its first-quarter report, with shares down over 2%, indicating market caution regarding its future performance.
See More
Somnigroup to Acquire Leggett & Platt for $2.5 Billion
- Acquisition Overview: Somnigroup International Inc. announced a definitive agreement to acquire Leggett & Platt, Inc. for $2.5 billion, with the transaction expected to close by the end of 2026, indicating a strong financial outlook as it is projected to enhance adjusted earnings per share in the first year.
- Shareholder Exchange Terms: Under the agreement, Leggett & Platt shareholders will receive 0.1455 shares of Somnigroup common stock for each share they own, resulting in Leggett & Platt shareholders owning approximately 9% of the combined company, ensuring their stake in the new entity.
- Financial Flexibility Improvement: The acquisition is expected to lower Somnigroup's net financial leverage and enhance financial flexibility, with an anticipated net positive impact of $50 million on adjusted EBITDA on a fully implemented annual run-rate basis, further strengthening the company's profitability.
- Operational Integration Plan: Post-acquisition, Leggett & Platt will operate as a separate business unit within Somnigroup, maintaining its offices in Carthage, Missouri, while continuing to honor existing supply agreements with customers, reflecting a commitment to customer relationships.
See More
Somnigroup to Acquire Leggett & Platt in $2.5B All-Stock Deal
- Acquisition Overview: Somnigroup International (SGI) has agreed to acquire Leggett & Platt (LEG) in an all-stock transaction valued at approximately $2.5 billion, where Leggett & Platt shareholders will receive 0.1455 shares of SGI common stock for each share they own, resulting in Leggett & Platt shareholders owning about 9% of the combined entity.
- Board Approval: The transaction has been unanimously approved by the boards of both companies and is anticipated to close by the end of 2026, subject to customary closing conditions including approval from Leggett & Platt shareholders and necessary regulatory approvals.
- Business Integration Plan: Following the closing, Leggett & Platt will operate as a separate business unit within SGI, maintaining its offices in Carthage, Missouri, with current chairman and CEO Karl Glassman continuing to lead the unit and assisting in the transition to a new CEO within twelve months post-closing.
- Financial Impact Expectations: The combined company is projected to generate approximately $11.2 billion in net sales and $1.7 billion in adjusted EBITDA for 2025, with an expected positive impact of $50 million in adjusted EBITDA from cost synergies in the first year after closing.
See More
Somnigroup Acquires Leggett & Platt for $2.5 Billion
- Acquisition Overview: Somnigroup has signed a definitive agreement to acquire Leggett & Platt in an all-stock transaction valued at approximately $2.5 billion, with Leggett & Platt shareholders receiving 0.1455 shares of Somnigroup common stock for each share they own, and the deal is expected to close by the end of 2026.
- Financial Impact Analysis: Post-merger, Somnigroup anticipates generating approximately $11.2 billion in net sales and $1.7 billion in adjusted EBITDA for 2025, enhancing its competitive position globally, while Leggett & Platt's net leverage stands at 2.4 times, with Somnigroup retaining its long-term debt.
- Operational Integration Plan: Leggett & Platt will operate as a separate business unit within Somnigroup, maintaining its offices in Carthage, Missouri, with current CEO Karl Glassman assisting in a smooth transition to ensure ongoing innovation in the bedding market.
- Strategic Synergies: This acquisition is expected to further advance Somnigroup's vertical integration strategy by enhancing engineering capabilities and diversifying end users, thereby increasing innovation and customer value, which is projected to create long-term value for shareholders.
See More
Somnigroup Acquires Leggett & Platt for $2.5 Billion
- Acquisition Overview: Somnigroup has signed a definitive agreement to acquire Leggett & Platt in an all-stock transaction valued at approximately $2.5 billion, with Leggett & Platt shareholders receiving 0.1455 shares of Somnigroup common stock for each share they own, and the deal is expected to close by the end of 2026.
- Financial Impact Analysis: Post-merger, the combined company is projected to achieve net sales of approximately $11.2 billion in 2025, with adjusted EBITDA around $1.7 billion and operating cash flow of $1.1 billion, indicating a robust financial foundation and cash-generating capacity that enhances Somnigroup's competitive position.
- Strategic Integration Benefits: The acquisition supports Somnigroup's vertical integration strategy by fostering closer collaboration between component engineering and mattress design, accelerating innovation cycles, and expanding market opportunities beyond bedding into non-bedding industries.
- Synergy Expectations: The merger is anticipated to create $50 million in cost synergies primarily from sourcing, operations, and product innovation, expected to be fully realized over three years, with approximately $10 million benefiting adjusted EBITDA in the first year post-closing.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Stock Price Movements of Various Companies
- Oracle AI Capabilities Boost: At the Customer Edge Summit, Oracle announced that its AI platform helped residential utility customers save $369 million in 2025, leading to a more than 9% increase in shares, indicating enhanced competitiveness in the cloud computing sector.
- Conagra CEO Transition: Conagra announced that John Brase will take over as CEO on June 1, resulting in a more than 5% drop in shares, reflecting market unease over leadership changes, with shares down over 17% in 2026.
- Allogene Therapeutics Clinical Success: The biotech company saw its shares soar nearly 30% after positive phase 2 data showed its CAR T treatment significantly improved cancer cell eradication in lymphoma patients, laying a strong foundation for future product line expansion.
- Goldman Sachs Earnings Beat: Despite its fixed income trading falling short of expectations, Goldman Sachs posted an earnings and revenue beat in its first-quarter report, with shares down over 2%, indicating market caution regarding its future performance.
See More
Somnigroup to Acquire Leggett & Platt for $2.5 Billion
- Acquisition Overview: Somnigroup International Inc. announced a definitive agreement to acquire Leggett & Platt, Inc. for $2.5 billion, with the transaction expected to close by the end of 2026, indicating a strong financial outlook as it is projected to enhance adjusted earnings per share in the first year.
- Shareholder Exchange Terms: Under the agreement, Leggett & Platt shareholders will receive 0.1455 shares of Somnigroup common stock for each share they own, resulting in Leggett & Platt shareholders owning approximately 9% of the combined company, ensuring their stake in the new entity.
- Financial Flexibility Improvement: The acquisition is expected to lower Somnigroup's net financial leverage and enhance financial flexibility, with an anticipated net positive impact of $50 million on adjusted EBITDA on a fully implemented annual run-rate basis, further strengthening the company's profitability.
- Operational Integration Plan: Post-acquisition, Leggett & Platt will operate as a separate business unit within Somnigroup, maintaining its offices in Carthage, Missouri, while continuing to honor existing supply agreements with customers, reflecting a commitment to customer relationships.
See More
Somnigroup to Acquire Leggett & Platt in $2.5B All-Stock Deal
- Acquisition Overview: Somnigroup International (SGI) has agreed to acquire Leggett & Platt (LEG) in an all-stock transaction valued at approximately $2.5 billion, where Leggett & Platt shareholders will receive 0.1455 shares of SGI common stock for each share they own, resulting in Leggett & Platt shareholders owning about 9% of the combined entity.
- Board Approval: The transaction has been unanimously approved by the boards of both companies and is anticipated to close by the end of 2026, subject to customary closing conditions including approval from Leggett & Platt shareholders and necessary regulatory approvals.
- Business Integration Plan: Following the closing, Leggett & Platt will operate as a separate business unit within SGI, maintaining its offices in Carthage, Missouri, with current chairman and CEO Karl Glassman continuing to lead the unit and assisting in the transition to a new CEO within twelve months post-closing.
- Financial Impact Expectations: The combined company is projected to generate approximately $11.2 billion in net sales and $1.7 billion in adjusted EBITDA for 2025, with an expected positive impact of $50 million in adjusted EBITDA from cost synergies in the first year after closing.
See More
Somnigroup Acquires Leggett & Platt for $2.5 Billion
- Acquisition Overview: Somnigroup has signed a definitive agreement to acquire Leggett & Platt in an all-stock transaction valued at approximately $2.5 billion, with Leggett & Platt shareholders receiving 0.1455 shares of Somnigroup common stock for each share they own, and the deal is expected to close by the end of 2026.
- Financial Impact Analysis: Post-merger, Somnigroup anticipates generating approximately $11.2 billion in net sales and $1.7 billion in adjusted EBITDA for 2025, enhancing its competitive position globally, while Leggett & Platt's net leverage stands at 2.4 times, with Somnigroup retaining its long-term debt.
- Operational Integration Plan: Leggett & Platt will operate as a separate business unit within Somnigroup, maintaining its offices in Carthage, Missouri, with current CEO Karl Glassman assisting in a smooth transition to ensure ongoing innovation in the bedding market.
- Strategic Synergies: This acquisition is expected to further advance Somnigroup's vertical integration strategy by enhancing engineering capabilities and diversifying end users, thereby increasing innovation and customer value, which is projected to create long-term value for shareholders.
See More
Somnigroup Acquires Leggett & Platt for $2.5 Billion
- Acquisition Overview: Somnigroup has signed a definitive agreement to acquire Leggett & Platt in an all-stock transaction valued at approximately $2.5 billion, with Leggett & Platt shareholders receiving 0.1455 shares of Somnigroup common stock for each share they own, and the deal is expected to close by the end of 2026.
- Financial Impact Analysis: Post-merger, the combined company is projected to achieve net sales of approximately $11.2 billion in 2025, with adjusted EBITDA around $1.7 billion and operating cash flow of $1.1 billion, indicating a robust financial foundation and cash-generating capacity that enhances Somnigroup's competitive position.
- Strategic Integration Benefits: The acquisition supports Somnigroup's vertical integration strategy by fostering closer collaboration between component engineering and mattress design, accelerating innovation cycles, and expanding market opportunities beyond bedding into non-bedding industries.
- Synergy Expectations: The merger is anticipated to create $50 million in cost synergies primarily from sourcing, operations, and product innovation, expected to be fully realized over three years, with approximately $10 million benefiting adjusted EBITDA in the first year post-closing.
See More
